Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8583393,conversion ratio,"Closer scrutiny discloses a conversion ratio of parent compound to N-desmethyl metabolite of 1.1 for chlorpromazine and of 2.2 for chlorimipramine, indicating the greater efficiency of chlorimipramine metabolism in all compartments.","Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,1.1,3139,DB01242,Clomipramine
,8583393,conversion ratio,"Closer scrutiny discloses a conversion ratio of parent compound to N-desmethyl metabolite of 1.1 for chlorpromazine and of 2.2 for chlorimipramine, indicating the greater efficiency of chlorimipramine metabolism in all compartments.","Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,2.2,3140,DB01242,Clomipramine
,8583393,conversion index,The expected high conversion index found in the liver (2.3) reaches its maximum of 5.4 in the lung.,"Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,2.3,3141,DB01242,Clomipramine
,8583393,conversion index,The expected high conversion index found in the liver (2.3) reaches its maximum of 5.4 in the lung.,"Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583393/),,5.4,3142,DB01242,Clomipramine
,598610,steady-state plasma concentrations,"Steady plasma clomipramine levels appeared to be related to dosage, the mean steady-state plasma concentrations between weeks 5 and 11 of treatment being 99 ng/ml, 145 ng/ml and 180 ng/ml, in patients receiving daily doses of 100, 150 and 200 mg clomipramine, respectively.",Pharmacokinetic studies in obsessional patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598610/),[ng] / [ml],99,10202,DB01242,Clomipramine
,598610,steady-state plasma concentrations,"Steady plasma clomipramine levels appeared to be related to dosage, the mean steady-state plasma concentrations between weeks 5 and 11 of treatment being 99 ng/ml, 145 ng/ml and 180 ng/ml, in patients receiving daily doses of 100, 150 and 200 mg clomipramine, respectively.",Pharmacokinetic studies in obsessional patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598610/),[ng] / [ml],145,10203,DB01242,Clomipramine
,598610,steady-state plasma concentrations,"Steady plasma clomipramine levels appeared to be related to dosage, the mean steady-state plasma concentrations between weeks 5 and 11 of treatment being 99 ng/ml, 145 ng/ml and 180 ng/ml, in patients receiving daily doses of 100, 150 and 200 mg clomipramine, respectively.",Pharmacokinetic studies in obsessional patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598610/),[ng] / [ml],180,10204,DB01242,Clomipramine
,3599564,brain to plasma concentration ratio,"The brain to plasma concentration ratio showed a constant value, 22.2 +/- 4.9, 30 minutes after the injection.",A pharmacokinetic study of clomipramine in regions of the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3599564/),,22.2,10968,DB01242,Clomipramine
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,66,21709,DB01242,Clomipramine
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,42,21710,DB01242,Clomipramine
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,228,21711,DB01242,Clomipramine
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,93,21712,DB01242,Clomipramine
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,82,21713,DB01242,Clomipramine
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,186,21714,DB01242,Clomipramine
less,2197816,oral bioavailability,Significant first-pass metabolism reduces oral bioavailability to less than 62 percent.,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),%,62,22476,DB01242,Clomipramine
,2197816,volume of distribution,The drug is widely distributed throughout the body (volume of distribution 9-25 L/kg) and is 90-98 percent protein-bound.,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),[l] / [kg],9-25,22477,DB01242,Clomipramine
,2197816,plasma half-life,"Clomipramine follows first-order elimination pharmacokinetics, with a plasma half-life of 20-24 hours.",Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),h,20-24,22478,DB01242,Clomipramine
,7361577,biological half-life,The biological half-life of amitriptyline in the myocardium was about 37.7 min.,"Myocardial pharmacokinetics of amitriptyline and clomipramine in the isolated, perfused rabbit heart. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361577/),min,37.7,27473,DB01242,Clomipramine
,7361577,accumulated amount at steady state,and the accumulated amount at steady state was calculated to be 1055 micrograms.,"Myocardial pharmacokinetics of amitriptyline and clomipramine in the isolated, perfused rabbit heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7361577/),μg,1055,27474,DB01242,Clomipramine
,1607145,tmax CMI,"Absorption was rapid (tmax CMI = 14 min), metabolism prompt (tmax DCMI = 17 or 18 min according to the breed) and elimination rapid from both plasma and brain tissue.",Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607145/),min,14,36278,DB01242,Clomipramine
,1607145,tmax DCMI,"Absorption was rapid (tmax CMI = 14 min), metabolism prompt (tmax DCMI = 17 or 18 min according to the breed) and elimination rapid from both plasma and brain tissue.",Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607145/),min,17,36279,DB01242,Clomipramine
,1607145,tmax DCMI,"Absorption was rapid (tmax CMI = 14 min), metabolism prompt (tmax DCMI = 17 or 18 min according to the breed) and elimination rapid from both plasma and brain tissue.",Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607145/),min,18,36280,DB01242,Clomipramine
,1607145,plasma t1/2,"The first two stages were similar in the two strains, but elimination of CMI from both plasma and brain was faster in the NMRI mice (plasma t1/2 = 53 min against 165 min in the CD1 mice).",Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607145/),min,53,36281,DB01242,Clomipramine
,1607145,plasma t1/2,"The first two stages were similar in the two strains, but elimination of CMI from both plasma and brain was faster in the NMRI mice (plasma t1/2 = 53 min against 165 min in the CD1 mice).",Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607145/),min,165,36282,DB01242,Clomipramine
,1607145,plasma t1/2,Both values were well below that reported for man (mean plasma t1/2 = 24 h).,Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607145/),h,24,36283,DB01242,Clomipramine
,24363733,retention time,"The retention time of internal standard (cisapride), clomipramine, and desmethyl clomipramine were 5.6 ± 0.2, 10.3 ± 0.3, and 9.5 ± 0.3 min, respectively.",A Simple Sample Preparation with HPLC-UV Method for Estimation of Clomipramine from Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363733/),min,5.6,36615,DB01242,Clomipramine
,24363733,retention time,"The retention time of internal standard (cisapride), clomipramine, and desmethyl clomipramine were 5.6 ± 0.2, 10.3 ± 0.3, and 9.5 ± 0.3 min, respectively.",A Simple Sample Preparation with HPLC-UV Method for Estimation of Clomipramine from Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363733/),min,10.3,36616,DB01242,Clomipramine
,24363733,retention time,"The retention time of internal standard (cisapride), clomipramine, and desmethyl clomipramine were 5.6 ± 0.2, 10.3 ± 0.3, and 9.5 ± 0.3 min, respectively.",A Simple Sample Preparation with HPLC-UV Method for Estimation of Clomipramine from Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363733/),min,9.5,36617,DB01242,Clomipramine
,10564058,oral bioavailability,"The mean oral bioavailability of clomipramine was 24.8% and 29.7%, respectively, in conscious rats and in rats anesthetized with ketamine/xylazine (30/3 mg/kg).",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,24.8,44100,DB01242,Clomipramine
,10564058,oral bioavailability,"The mean oral bioavailability of clomipramine was 24.8% and 29.7%, respectively, in conscious rats and in rats anesthetized with ketamine/xylazine (30/3 mg/kg).",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,29.7,44101,DB01242,Clomipramine
,10564058,absolute bioavailability,"When given sublingually in isotonic saline at a dose of 50 mg/kg, clomipramine was rapidly absorbed, and the mean absolute bioavailability (36.2%) was increased over oral dosing.",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,36.2,44102,DB01242,Clomipramine
,10564058,AUC,"The mean AUC values of clomipramine were 2258 +/- 1762 ng.h/mL and 1891 +/- 867 ng.h/mL after oral administration to conscious and anesthetized rats, respectively, and 3303 +/- 1576 ng.h/mL after sublingual administration to anesthetized rats.",Increased bioavailability of clomipramine after sublingual administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),[h·ng] / [ml],2258,44103,DB01242,Clomipramine
,10564058,AUC,"The mean AUC values of clomipramine were 2258 +/- 1762 ng.h/mL and 1891 +/- 867 ng.h/mL after oral administration to conscious and anesthetized rats, respectively, and 3303 +/- 1576 ng.h/mL after sublingual administration to anesthetized rats.",Increased bioavailability of clomipramine after sublingual administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),[h·ng] / [ml],1891,44104,DB01242,Clomipramine
,10564058,AUC,"The mean AUC values of clomipramine were 2258 +/- 1762 ng.h/mL and 1891 +/- 867 ng.h/mL after oral administration to conscious and anesthetized rats, respectively, and 3303 +/- 1576 ng.h/mL after sublingual administration to anesthetized rats.",Increased bioavailability of clomipramine after sublingual administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),[h·ng] / [ml],3303,44105,DB01242,Clomipramine
,10564058,bioavailability,"Sublingual administration (5 mg/kg doses) of clomipramine formulated with a permeation enhancer, 2-hydroxypropyl beta-cyclodextrin, further increased the sublingual bioavailability to 57.1%.",Increased bioavailability of clomipramine after sublingual administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564058/),%,57.1,44106,DB01242,Clomipramine
,16353581,area under the curve AUC,The area under the curve AUC for ACTH after clomipramine was 6202 +/- 976 pg/ml x 150 minutes for tile obese before weight loss and 3274 +/- 512 pg/ml x 150 minutes for the controls and the difference was significant at the level of p=0.052.,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[pg] / [150·min·ml],6202,62335,DB01242,Clomipramine
,16353581,area under the curve AUC,The area under the curve AUC for ACTH after clomipramine was 6202 +/- 976 pg/ml x 150 minutes for tile obese before weight loss and 3274 +/- 512 pg/ml x 150 minutes for the controls and the difference was significant at the level of p=0.052.,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[pg] / [150·min·ml],3274,62336,DB01242,Clomipramine
,16353581,peak value,The cortisol peak value after clomipramine was 163.71 +/- 14.31 ng/ml in the non-obese and 214.66 +/- 12.59 ng/ml in the obese (p=0.025).,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[ng] / [ml],163.71,62337,DB01242,Clomipramine
,16353581,peak value,The cortisol peak value after clomipramine was 163.71 +/- 14.31 ng/ml in the non-obese and 214.66 +/- 12.59 ng/ml in the obese (p=0.025).,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[ng] / [ml],214.66,62338,DB01242,Clomipramine
,1277478,peak drug concentrations,"For both amines, the detection limit is 0.3 mug/liter; Six healthy volunteers who received a single oral dose of 50 mg of clomipramine hydrochloride showed peak drug concentrations in the blood 3 to 5 h after administration, ranging between 14.4 and 30.1 mug/liter.","Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277478/),[μg] / [l],14.4 and 30.1,75235,DB01242,Clomipramine
,1277478,Plasma/whole blood concentration ratios,"Plasma/whole blood concentration ratios varied from 0.70 to 1.20, and the cumulative renal elimination from 0 to 72 h is less than 0.2% of the dose.","Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277478/),,0.70 to 1.20,75236,DB01242,Clomipramine
,9673963,time of maximum plasma concentration (tmax),"Following a single dose of clomipramine, time of maximum plasma concentration (tmax) of clomipramine was 0.75-3.1 h, maximum plasma concentration (Cmax) was 16-310 ng/mL and elimination half-life (t1/2el) was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/ mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,0.75-3.1,100150,DB01242,Clomipramine
,9673963,maximum plasma concentration (Cmax),"Following a single dose of clomipramine, time of maximum plasma concentration (tmax) of clomipramine was 0.75-3.1 h, maximum plasma concentration (Cmax) was 16-310 ng/mL and elimination half-life (t1/2el) was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/ mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),[ng] / [ml],16-310,100151,DB01242,Clomipramine
,9673963,elimination half-life (t1/2el),"Following a single dose of clomipramine, time of maximum plasma concentration (tmax) of clomipramine was 0.75-3.1 h, maximum plasma concentration (Cmax) was 16-310 ng/mL and elimination half-life (t1/2el) was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/ mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,1.2-16,100152,DB01242,Clomipramine
,9673963,tmax,"Following a single dose of clomipramine, time of maximum plasma concentration (tmax) of clomipramine was 0.75-3.1 h, maximum plasma concentration (Cmax) was 16-310 ng/mL and elimination half-life (t1/2el) was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/ mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,1.4-8.8,100153,DB01242,Clomipramine
,9673963,Cmax,"Following a single dose of clomipramine, time of maximum plasma concentration (tmax) of clomipramine was 0.75-3.1 h, maximum plasma concentration (Cmax) was 16-310 ng/mL and elimination half-life (t1/2el) was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/ mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),[ng] / [ml],21-134,100154,DB01242,Clomipramine
,9673963,t1/2el,"Following a single dose of clomipramine, time of maximum plasma concentration (tmax) of clomipramine was 0.75-3.1 h, maximum plasma concentration (Cmax) was 16-310 ng/mL and elimination half-life (t1/2el) was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/ mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,1.2-2.3,100155,DB01242,Clomipramine
,9673963,tmax,"Following multiple dosing, there was a numeric increase in these parameters; tmax of clomipramine was 3-8 h, Cmax was 43-222 ng/mL and t1/2el was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,3-8,100156,DB01242,Clomipramine
,9673963,Cmax,"Following multiple dosing, there was a numeric increase in these parameters; tmax of clomipramine was 3-8 h, Cmax was 43-222 ng/mL and t1/2el was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),[ng] / [ml],43-222,100157,DB01242,Clomipramine
,9673963,t1/2el,"Following multiple dosing, there was a numeric increase in these parameters; tmax of clomipramine was 3-8 h, Cmax was 43-222 ng/mL and t1/2el was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,1.2-16,100158,DB01242,Clomipramine
,9673963,tmax,"Following multiple dosing, there was a numeric increase in these parameters; tmax of clomipramine was 3-8 h, Cmax was 43-222 ng/mL and t1/2el was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,1.4-8.8,100159,DB01242,Clomipramine
,9673963,Cmax,"Following multiple dosing, there was a numeric increase in these parameters; tmax of clomipramine was 3-8 h, Cmax was 43-222 ng/mL and t1/2el was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),[ng] / [ml],21-134,100160,DB01242,Clomipramine
,9673963,t1/2el,"Following multiple dosing, there was a numeric increase in these parameters; tmax of clomipramine was 3-8 h, Cmax was 43-222 ng/mL and t1/2el was 1.2-16 h; tmax of desmethylclomipramine was 1.4-8.8 h, Cmax was 21-134 ng/mL and t1/2el was 1.2-2.3 h.",The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673963/),h,1.2-2.3,100161,DB01242,Clomipramine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB01242,Clomipramine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB01242,Clomipramine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB01242,Clomipramine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB01242,Clomipramine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB01242,Clomipramine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB01242,Clomipramine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB01242,Clomipramine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],58,112118,DB01242,Clomipramine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],87,112119,DB01242,Clomipramine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],223,112120,DB01242,Clomipramine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],49,112121,DB01242,Clomipramine
,11205739,CL(INT),Simulated PK studies were done using a linear first-pass model with CL(INT) values ranging from 15 L/HR to 900 L/HR.,The role of metabolites in bioequivalency assessment. Highly variable drugs with linear kinetics and first-pass effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205739/),l,15,113761,DB01242,Clomipramine
,11205739,CL(INT),Simulated PK studies were done using a linear first-pass model with CL(INT) values ranging from 15 L/HR to 900 L/HR.,The role of metabolites in bioequivalency assessment. Highly variable drugs with linear kinetics and first-pass effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205739/),l,900,113762,DB01242,Clomipramine
,17348896,MR,"Statistically significant gender-related differences were detected in MR and Cl/F, where female cats had a higher mean MR (0.53) and faster Cl/F (0.36 L/h.kg) than males (0.36 and 0.21 L/h.kg, respectively).",Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348896/),,0.53,126845,DB01242,Clomipramine
,17348896,Cl/F,"Statistically significant gender-related differences were detected in MR and Cl/F, where female cats had a higher mean MR (0.53) and faster Cl/F (0.36 L/h.kg) than males (0.36 and 0.21 L/h.kg, respectively).",Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348896/),[l] / [h·kg],0.36,126846,DB01242,Clomipramine
,17348896,Cl/F,"Statistically significant gender-related differences were detected in MR and Cl/F, where female cats had a higher mean MR (0.53) and faster Cl/F (0.36 L/h.kg) than males (0.36 and 0.21 L/h.kg, respectively).",Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348896/),[l] / [h·kg],0.21,126847,DB01242,Clomipramine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),mg,2.67,128245,DB01242,Clomipramine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),[ng] / [ml],1.42,128246,DB01242,Clomipramine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),mg,18.6,128247,DB01242,Clomipramine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),[ng] / [ml],4.19,128248,DB01242,Clomipramine
,10630784,Accumulation ratios,"Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine.",Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),,1.4,132941,DB01242,Clomipramine
,10630784,Accumulation ratios,"Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine.",Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),,1.6,132942,DB01242,Clomipramine
,10630784,Accumulation ratios,"Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine.",Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),,3.8,132943,DB01242,Clomipramine
,10630784,Accumulation ratios,"Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine.",Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),,2.1,132944,DB01242,Clomipramine
,10630784,Accumulation ratios,"Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine.",Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),,3.7,132945,DB01242,Clomipramine
,10630784,Accumulation ratios,"Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine.",Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),,7.6,132946,DB01242,Clomipramine
<,10630784,Terminal half-life,Terminal half-life increased slightly (1.6-fold for clomipramine and 1.2-fold for desmethylclomipramine) with repeated-dose administration but remained short in all groups (< or = 4 hours).,Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630784/),h,4,132947,DB01242,Clomipramine
>,10599932,metabolic ratio,"The CYP2D6 phenotype, determined when the patient received the antidepressant comedication, characterized a poor metabolizer status (dextromethorphan metabolic ratio >0.3), despite a heterozygous genotype containing a wild-type allele with extensive metabolic capacity and a mutant non-functional allele (CYP2D6*1A/CYP2D6*4A).",Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599932/),,0.3,133345,DB01242,Clomipramine
,10505580,oral clearance,"The median (25% and 75% quartiles, respectively) oral clearance of C was 12.7 L/hr (11.6, 30.6) in Japanese patients receiving C monotherapy, 18.1 L/hr (5.6, 31.8) in Japanese patients receiving C plus BZDs, 62.7 L/hr (40.0, 90.6) in Swedish patients receiving C monotherapy, and 56.5 L/hr (34.3, 74.1) in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),[l] / [h],12.7,137225,DB01242,Clomipramine
,10505580,oral clearance,"The median (25% and 75% quartiles, respectively) oral clearance of C was 12.7 L/hr (11.6, 30.6) in Japanese patients receiving C monotherapy, 18.1 L/hr (5.6, 31.8) in Japanese patients receiving C plus BZDs, 62.7 L/hr (40.0, 90.6) in Swedish patients receiving C monotherapy, and 56.5 L/hr (34.3, 74.1) in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),[l] / [h],18.1,137226,DB01242,Clomipramine
,10505580,oral clearance,"The median (25% and 75% quartiles, respectively) oral clearance of C was 12.7 L/hr (11.6, 30.6) in Japanese patients receiving C monotherapy, 18.1 L/hr (5.6, 31.8) in Japanese patients receiving C plus BZDs, 62.7 L/hr (40.0, 90.6) in Swedish patients receiving C monotherapy, and 56.5 L/hr (34.3, 74.1) in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),[l] / [h],62.7,137227,DB01242,Clomipramine
,10505580,oral clearance,"The median (25% and 75% quartiles, respectively) oral clearance of C was 12.7 L/hr (11.6, 30.6) in Japanese patients receiving C monotherapy, 18.1 L/hr (5.6, 31.8) in Japanese patients receiving C plus BZDs, 62.7 L/hr (40.0, 90.6) in Swedish patients receiving C monotherapy, and 56.5 L/hr (34.3, 74.1) in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),[l] / [h],56.5,137228,DB01242,Clomipramine
,10505580,C/DC,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,1.08,137229,DB01242,Clomipramine
,10505580,C/DC,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,0.90,137230,DB01242,Clomipramine
,10505580,C/DC,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,0.51,137231,DB01242,Clomipramine
,10505580,C/DC,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,0.49,137232,DB01242,Clomipramine
,10505580,plasma concentration ratios,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,1.08,137233,DB01242,Clomipramine
,10505580,plasma concentration ratios,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,0.90,137234,DB01242,Clomipramine
,10505580,plasma concentration ratios,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,0.51,137235,DB01242,Clomipramine
,10505580,plasma concentration ratios,"The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs.",Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505580/),,0.49,137236,DB01242,Clomipramine
,10974613,Half-lives,"Half-lives were similar in serum and brain with 7.8 versus 6.2 h and 5.5 versus 5.0 h for clomipramine and desmethylclomipramine, respectively.",Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974613/),h,7.8,146369,DB01242,Clomipramine
,10974613,Half-lives,"Half-lives were similar in serum and brain with 7.8 versus 6.2 h and 5.5 versus 5.0 h for clomipramine and desmethylclomipramine, respectively.",Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974613/),h,6.2,146370,DB01242,Clomipramine
,10974613,Half-lives,"Half-lives were similar in serum and brain with 7.8 versus 6.2 h and 5.5 versus 5.0 h for clomipramine and desmethylclomipramine, respectively.",Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974613/),h,5.5,146371,DB01242,Clomipramine
,10974613,Half-lives,"Half-lives were similar in serum and brain with 7.8 versus 6.2 h and 5.5 versus 5.0 h for clomipramine and desmethylclomipramine, respectively.",Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974613/),h,5.0,146372,DB01242,Clomipramine
,2918477,half-life,"Acute and chronic (i.e., every half-life of 130 min for five half-lives) administration of CMI (10 or 20 mg/kg i.p.) had opposite effects; the former potentiated morphine analgesia and the latter inhibited it.",Pharmacokinetic patterns of repeated administration of antidepressants in animals. Their relevance in a study of the influence of clomipramine on morphine analgesia in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2918477/),min,130,156808,DB01242,Clomipramine
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB01242,Clomipramine
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],99,169598,DB01242,Clomipramine
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],56,169599,DB01242,Clomipramine
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],66,169600,DB01242,Clomipramine
,8181196,total median clearance,"The total median clearance of clomipramine was 99 L.hr-1 (range, 68 to 210) in the EMs/EMm subjects, 56 L.hr-1 (range, 37 to 183) in the PMs/EMm subjects, 66 L.hr-1 (range, 37 to 89) in the EMs/PMm subjects, and 43 L.hr-1 in the PMs/PMm subject.",Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181196/),[l] / [h],43,169601,DB01242,Clomipramine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[mg] / [kg],0.44,171181,DB01242,Clomipramine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[ng] / [ml],24.5,171182,DB01242,Clomipramine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[mg] / [kg],0.11,171183,DB01242,Clomipramine
,21336575,Kd,"The mean Kd values, expressed as the dose or plasma concentration at which 50% of NET was occupied, were 0.44 mg/kg and 24.5 ng/ml for clomipramine and 0.11 mg/kg and 4.4 ng/ml for desmethylclomipramine.","NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336575/),[ng] / [ml],4.4,171184,DB01242,Clomipramine
,21801198,half-life,We calculated a half-life value of 42 ± 16 h for clomipramine in neonates.,Clomipramine concentration and withdrawal symptoms in 10 neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801198/),h,42,173896,DB01242,Clomipramine
,21801198,half-life,"In neonates, clomipramine is eliminated with a half-life value of 42 h, compared with 20 h in adults.",Clomipramine concentration and withdrawal symptoms in 10 neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801198/),h,42,173897,DB01242,Clomipramine
,21801198,half-life,"In neonates, clomipramine is eliminated with a half-life value of 42 h, compared with 20 h in adults.",Clomipramine concentration and withdrawal symptoms in 10 neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801198/),h,20,173898,DB01242,Clomipramine
,22022866,Plasma concentration,Plasma concentration of CPM at a steady state in OS rats (0.20 ± 0.02 μg/mL) was significantly lower than that in control rats (0.30 ± 0.02 μg/mL).,Effect of oxidative stress on the pharmacokinetics of clomipramine in rats treated with ferric-nitrilotriacetate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22022866/),[μg] / [ml],0.20,182527,DB01242,Clomipramine
,22022866,Plasma concentration,Plasma concentration of CPM at a steady state in OS rats (0.20 ± 0.02 μg/mL) was significantly lower than that in control rats (0.30 ± 0.02 μg/mL).,Effect of oxidative stress on the pharmacokinetics of clomipramine in rats treated with ferric-nitrilotriacetate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22022866/),[μg] / [ml],0.30,182528,DB01242,Clomipramine
,7903373,area under the plasma concentration-time curve (AUC0-24),"Ingestion of chlorimipramine resulted in an area under the plasma concentration-time curve (AUC0-24) for parent drug plus metabolites 5-fold higher than that observed in the same subjects following chlorpromazine intake (600 +/- 87 and 124 +/- 14 ng mL-1, respectively).","Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903373/),[ng] / [ml],600,186589,DB01242,Clomipramine
,7903373,area under the plasma concentration-time curve (AUC0-24),"Ingestion of chlorimipramine resulted in an area under the plasma concentration-time curve (AUC0-24) for parent drug plus metabolites 5-fold higher than that observed in the same subjects following chlorpromazine intake (600 +/- 87 and 124 +/- 14 ng mL-1, respectively).","Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903373/),[ng] / [ml],124,186590,DB01242,Clomipramine
,7903373,peak value,"Plasma chlorimipramine levels reached a mean peak value of 43.8 ng mL-1, which occurred 2 h after administration.","Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903373/),[ng] / [ml],43.8,186591,DB01242,Clomipramine
,16846464,elimination rate constant,Intravenous clomipramine best fit a two-compartmental model yielding an elimination rate constant of 0.037-0.09 h(-1) from which a mean half-life of 12.3 h was calculated.,Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),1/[h],0.037-0.09,186721,DB01242,Clomipramine
,16846464,half-life,Intravenous clomipramine best fit a two-compartmental model yielding an elimination rate constant of 0.037-0.09 h(-1) from which a mean half-life of 12.3 h was calculated.,Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,12.3,186722,DB01242,Clomipramine
,16846464,clearance,"Mean clomipramine AUC(0--infinity) (ngxh/mL), clearance (L/hxkg), V(ss) (L/kg) and MRT (h) values were 652.5, 0.393, 5.0, and 13.5, respectively.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),[l] / [kg],652.5,186723,DB01242,Clomipramine
,16846464,MRT (h),"Mean clomipramine AUC(0--infinity) (ngxh/mL), clearance (L/hxkg), V(ss) (L/kg) and MRT (h) values were 652.5, 0.393, 5.0, and 13.5, respectively.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),,13.5,186724,DB01242,Clomipramine
,16846464,C(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,948.3,186725,DB01242,Clomipramine
,16846464,C(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,87.5,186726,DB01242,Clomipramine
,16846464,C(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,613.8,186727,DB01242,Clomipramine
,16846464,C(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,34.8,186728,DB01242,Clomipramine
,16846464,C(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,12.8,186729,DB01242,Clomipramine
,16846464,T(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,613.8,186730,DB01242,Clomipramine
,16846464,T(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,34.8,186731,DB01242,Clomipramine
,16846464,T(max),"Noncompartmental analysis yielded mean AUC(0--30 h) (ngxh/mL), C(max) (ng/mL) and T(max) (h) of 948.3, 87.5 and 6.2 for clomipramine, and 613.8, 34.8, and 12.8 for DCMP respectively after oral administration.",Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),h,12.8,186732,DB01242,Clomipramine
,16846464,bioavailability,Clomipramine bioavailability was 90%.,Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846464/),%,90,186733,DB01242,Clomipramine
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB01242,Clomipramine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB01242,Clomipramine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB01242,Clomipramine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB01242,Clomipramine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB01242,Clomipramine
,10630783,Time to peak plasma concentrations,Time to peak plasma concentrations of clomipramine and desmethylclomipramine following oral administration was 1.2 hours.,Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630783/),h,1.2,196113,DB01242,Clomipramine
,10630783,elimination half-life,"For clomipramine, after IV administration, elimination half-life was 5 hours, mean residence time was 3 hours, and plasma clearance was 1.4 L/h/kg.",Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630783/),h,5,196114,DB01242,Clomipramine
,10630783,mean residence time,"For clomipramine, after IV administration, elimination half-life was 5 hours, mean residence time was 3 hours, and plasma clearance was 1.4 L/h/kg.",Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630783/),h,3,196115,DB01242,Clomipramine
,10630783,plasma clearance,"For clomipramine, after IV administration, elimination half-life was 5 hours, mean residence time was 3 hours, and plasma clearance was 1.4 L/h/kg.",Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630783/),[l] / [h·kg],1.4,196116,DB01242,Clomipramine
,10630783,systemic bioavailability,"Values for mean residence time and terminal half-life following oral administration were similar to values obtained following IV administration, and systemic bioavailability was approximately 20% for clomipramine and 140% for desmethylclomipramine, indicating fast absorption of clomipramine from the gastrointestinal tract and extensive first-pass metabolism.",Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630783/),%,20,196117,DB01242,Clomipramine
,10630783,systemic bioavailability,"Values for mean residence time and terminal half-life following oral administration were similar to values obtained following IV administration, and systemic bioavailability was approximately 20% for clomipramine and 140% for desmethylclomipramine, indicating fast absorption of clomipramine from the gastrointestinal tract and extensive first-pass metabolism.",Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630783/),%,140,196118,DB01242,Clomipramine
,3385649,plasma half-life,"The plasma half-life (127 min) in the Swiss CD1 mouse was used as a basis for chronic administration, which was strictly every half-life as in clinical use.",Pharmacokinetic patterns of repeated administration of antidepressants in animals. I. Implications for antinociceptive action of clomipramine in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385649/),min,127,205520,DB01242,Clomipramine
,8485374,detection limits,"This rapid (6 min) and highly sensitive methodology (detection limits 0.5 ng/mL and 2 ng/mL for clomipramine and desmethylclomipramine, respectively; S/N = 3, 0.001 aufs) allows pharmacokinetic studies and drug monitoring of the two compounds.",Drug monitoring of clomipramine and desmethylclomipramine in depressed patients using a new liquid chromatographic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485374/),[ng] / [ml],0.5,210983,DB01242,Clomipramine
,8485374,detection limits,"This rapid (6 min) and highly sensitive methodology (detection limits 0.5 ng/mL and 2 ng/mL for clomipramine and desmethylclomipramine, respectively; S/N = 3, 0.001 aufs) allows pharmacokinetic studies and drug monitoring of the two compounds.",Drug monitoring of clomipramine and desmethylclomipramine in depressed patients using a new liquid chromatographic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485374/),[ng] / [ml],2,210984,DB01242,Clomipramine
,8485374,S/N,"This rapid (6 min) and highly sensitive methodology (detection limits 0.5 ng/mL and 2 ng/mL for clomipramine and desmethylclomipramine, respectively; S/N = 3, 0.001 aufs) allows pharmacokinetic studies and drug monitoring of the two compounds.",Drug monitoring of clomipramine and desmethylclomipramine in depressed patients using a new liquid chromatographic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485374/),,3,210985,DB01242,Clomipramine
,8485374,S/N,"This rapid (6 min) and highly sensitive methodology (detection limits 0.5 ng/mL and 2 ng/mL for clomipramine and desmethylclomipramine, respectively; S/N = 3, 0.001 aufs) allows pharmacokinetic studies and drug monitoring of the two compounds.",Drug monitoring of clomipramine and desmethylclomipramine in depressed patients using a new liquid chromatographic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485374/),aufs,0.001,210986,DB01242,Clomipramine
,30564074,extraction recoveries,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),%,69-84,227547,DB01242,Clomipramine
,30564074,enrichment factors,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),,345-420,227548,DB01242,Clomipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,11.6-35.8,239135,DB01242,Clomipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,20.8,239136,DB01242,Clomipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,20.1--39.6,239137,DB01242,Clomipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),,24.7,239138,DB01242,Clomipramine
,21401603,plasma concentration,Mean plasma concentration of clomipramine at steady state during continuous infusion (17.5µg/min/kg) in hyperlipidaemic rats (0.45±0.01µg/ml) was significantly higher than that in the control rats (0.30±0.02µg/ml).,"Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401603/),[μg] / [kg·min],17.5,239341,DB01242,Clomipramine
,21401603,plasma concentration,Mean plasma concentration of clomipramine at steady state during continuous infusion (17.5µg/min/kg) in hyperlipidaemic rats (0.45±0.01µg/ml) was significantly higher than that in the control rats (0.30±0.02µg/ml).,"Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401603/),[μg] / [ml],0.45,239342,DB01242,Clomipramine
,21401603,plasma concentration,Mean plasma concentration of clomipramine at steady state during continuous infusion (17.5µg/min/kg) in hyperlipidaemic rats (0.45±0.01µg/ml) was significantly higher than that in the control rats (0.30±0.02µg/ml).,"Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401603/),[μg] / [ml],0.30,239343,DB01242,Clomipramine
,21401603,plasma unbound fraction,"However, the plasma unbound fraction in hyperlipidaemic rats (0.98±0.05%) was significantly lower than that of the control rats (6.51±0.62%).","Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401603/),%,0.98,239344,DB01242,Clomipramine
,21401603,plasma unbound fraction,"However, the plasma unbound fraction in hyperlipidaemic rats (0.98±0.05%) was significantly lower than that of the control rats (6.51±0.62%).","Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401603/),%,6.51,239345,DB01242,Clomipramine
,6697642,Elimination t1/2,Elimination t1/2 after intravenous dosing was (mean +/- SE) 23 +/- 1.9 hr.,Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697642/),h,23,240839,DB01242,Clomipramine
,6697642,Volume of distribution,Volume of distribution by the area method was 30.9 +/- 3.5 l/kg and total metabolic clearance was 15.9 +/- 1.5 ml/min/kg.,Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697642/),[l] / [kg],30.9,240840,DB01242,Clomipramine
,6697642,total metabolic clearance,Volume of distribution by the area method was 30.9 +/- 3.5 l/kg and total metabolic clearance was 15.9 +/- 1.5 ml/min/kg.,Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697642/),[ml] / [kg·min],15.9,240841,DB01242,Clomipramine
,6697642,Plasma protein binding,"Plasma protein binding of trimipramine, as determined by equilibrium dialysis, averaged 94.9%, with a range of 93.8% to 96.4%.",Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697642/),%,94.9,240842,DB01242,Clomipramine
,6697642,Peak plasma level,Peak plasma level attained was 28.2 +/- 4.4 ng/ml at 3.1 +/- 0.6 hr after oral dosing.,Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697642/),[ng] / [ml],28.2,240843,DB01242,Clomipramine
,6697642,Absolute bioavailability,Absolute bioavailability was 41.4% +/- 4.4% (range of 17.8% to 62.7%).,Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697642/),%,41.4,240844,DB01242,Clomipramine
,8991493,Cmax,The geometric mean values for the variable Cmax were 31.3 ng mL-1 for the reference and 31.6 ng mL-1 for the test product in study 1.,Relative bioavailability of four clomipramine hydrochloride tablet products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[ng] / [ml],31.3,249267,DB01242,Clomipramine
,8991493,Cmax,The geometric mean values for the variable Cmax were 31.3 ng mL-1 for the reference and 31.6 ng mL-1 for the test product in study 1.,Relative bioavailability of four clomipramine hydrochloride tablet products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[ng] / [ml],31.6,249268,DB01242,Clomipramine
,8991493,AUC,"The geometric mean values for the variable AUC were 736 ng h mL-1 and 753 ng h mL-1 for the reference and test, respectively.",Relative bioavailability of four clomipramine hydrochloride tablet products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[h·ng] / [ml],736,249269,DB01242,Clomipramine
,8991493,AUC,"The geometric mean values for the variable AUC were 736 ng h mL-1 and 753 ng h mL-1 for the reference and test, respectively.",Relative bioavailability of four clomipramine hydrochloride tablet products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[h·ng] / [ml],753,249270,DB01242,Clomipramine
,8991493,Cmax,"In study 2, the geometric mean Cmax values were 25.8 ng mL-1 and 23.9 ng mL-1 for the reference and test respectively; the geometric mean AUC values were 569 ng h mL-1 and 547 ng h mL-1.",Relative bioavailability of four clomipramine hydrochloride tablet products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[ng] / [ml],25.8,249271,DB01242,Clomipramine
,8991493,Cmax,"In study 2, the geometric mean Cmax values were 25.8 ng mL-1 and 23.9 ng mL-1 for the reference and test respectively; the geometric mean AUC values were 569 ng h mL-1 and 547 ng h mL-1.",Relative bioavailability of four clomipramine hydrochloride tablet products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[ng] / [ml],23.9,249272,DB01242,Clomipramine
,8991493,AUC,"In study 2, the geometric mean Cmax values were 25.8 ng mL-1 and 23.9 ng mL-1 for the reference and test respectively; the geometric mean AUC values were 569 ng h mL-1 and 547 ng h mL-1.",Relative bioavailability of four clomipramine hydrochloride tablet products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[h·ng] / [ml],569,249273,DB01242,Clomipramine
,8991493,AUC,"In study 2, the geometric mean Cmax values were 25.8 ng mL-1 and 23.9 ng mL-1 for the reference and test respectively; the geometric mean AUC values were 569 ng h mL-1 and 547 ng h mL-1.",Relative bioavailability of four clomipramine hydrochloride tablet products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991493/),[h·ng] / [ml],547,249274,DB01242,Clomipramine
,7393820,half-life,"Their mean clomipramine half-life was 36 hours and mean plasma clomipramine clearance 73 litres per hour, with a wide range in each case.",Single oral dose pharmacokinetics of clomipramine in depressed patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7393820/),h,36,259536,DB01242,Clomipramine
,7393820,plasma clomipramine clearance,"Their mean clomipramine half-life was 36 hours and mean plasma clomipramine clearance 73 litres per hour, with a wide range in each case.",Single oral dose pharmacokinetics of clomipramine in depressed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7393820/),[l] / [h],73,259537,DB01242,Clomipramine
,23675185,flow rate,"Azelastine and internal standard (IS, clomipramine) were separated using a mobile phase of acetonitrile:(5 mM)-ammonium acetate solution (70:30, v/v, pH=6.4) with flow rate of 0.25 mL/min over YMC C8 column.",Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675185/),[ml] / [min],0.25,260160,DB01242,Clomipramine
<,23675185,Total run-time,Total run-time (<2.0 min) and linearity (10 (LLOQ) ~5000 pg/mL) were good.,Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675185/),min,2.0,260161,DB01242,Clomipramine
,23675185,peak plasma concentrations (Cmax,"The mean peak plasma concentrations (Cmax ± SD) of 1.02 ± 0.37 and 1.10 ± 0.43 ng/mL were reached at 5.9 and 5.6 h for reference and test azelastine, respectively.",Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675185/),[ng] / [ml],1.02,260162,DB01242,Clomipramine
,23675185,peak plasma concentrations (Cmax,"The mean peak plasma concentrations (Cmax ± SD) of 1.02 ± 0.37 and 1.10 ± 0.43 ng/mL were reached at 5.9 and 5.6 h for reference and test azelastine, respectively.",Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675185/),[ng] / [ml],1.10,260163,DB01242,Clomipramine
,23675185,total area under the curve (AUC0-infinity),"The mean total area under the curve (AUC0-infinity) were 25.96 ± 10.84 and 28.24 ± 11.09 ng·h/mL for reference and test formulations, respectively.",Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675185/),[h·ng] / [ml],25.96,260164,DB01242,Clomipramine
,23675185,total area under the curve (AUC0-infinity),"The mean total area under the curve (AUC0-infinity) were 25.96 ± 10.84 and 28.24 ± 11.09 ng·h/mL for reference and test formulations, respectively.",Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23675185/),[h·ng] / [ml],28.24,260165,DB01242,Clomipramine
,6939006,relative CI clearance,The mean relative CI clearance after repeated i.m. injections was 0.441 kg-1 hour-1.,Pharmacokinetics of clomipramine in depressive patients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6939006/),1/[h·kg],0.441,271719,DB01242,Clomipramine
,11185671,Cmax,"In the single-dose study, the mean Cmax and AUC values of CMI were 63.37 ng/mL-1 and 1375.38 ng.h/mL-1 for the reference product and 32.55 ng/mL-1 and 1285.26 ng.h/mL-1 for the test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),[ng] / [ml],63.37,273205,DB01242,Clomipramine
,11185671,Cmax,"In the single-dose study, the mean Cmax and AUC values of CMI were 63.37 ng/mL-1 and 1375.38 ng.h/mL-1 for the reference product and 32.55 ng/mL-1 and 1285.26 ng.h/mL-1 for the test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),[ng] / [ml],32.55,273206,DB01242,Clomipramine
,11185671,AUC,"In the single-dose study, the mean Cmax and AUC values of CMI were 63.37 ng/mL-1 and 1375.38 ng.h/mL-1 for the reference product and 32.55 ng/mL-1 and 1285.26 ng.h/mL-1 for the test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),[h·ng] / [ml],1375.38,273207,DB01242,Clomipramine
,11185671,AUC,"In the single-dose study, the mean Cmax and AUC values of CMI were 63.37 ng/mL-1 and 1375.38 ng.h/mL-1 for the reference product and 32.55 ng/mL-1 and 1285.26 ng.h/mL-1 for the test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),[h·ng] / [ml],1285.26,273208,DB01242,Clomipramine
,11185671,beta,"The mean beta and MRT values of CMI were 0.030 h-1 and 47.21 h for the reference product and 0.026 h-1 and 55.63 h for test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),1/[h],0.030,273209,DB01242,Clomipramine
,11185671,beta,"The mean beta and MRT values of CMI were 0.030 h-1 and 47.21 h for the reference product and 0.026 h-1 and 55.63 h for test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),1/[h],0.026,273210,DB01242,Clomipramine
,11185671,MRT,"The mean beta and MRT values of CMI were 0.030 h-1 and 47.21 h for the reference product and 0.026 h-1 and 55.63 h for test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),h,47.21,273211,DB01242,Clomipramine
,11185671,MRT,"The mean beta and MRT values of CMI were 0.030 h-1 and 47.21 h for the reference product and 0.026 h-1 and 55.63 h for test product, respectively.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),h,55.63,273212,DB01242,Clomipramine
,11185671,Cavss,"Results showed that after the multiple-dose study, the mean clomipramine plus demethylclomipramine values of Cavss were 406.2 ng/mL-1 for the reference and 328.6 ng/mL-1 for the sustained-release dosage form.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),[ng] / [ml],406.2,273213,DB01242,Clomipramine
,11185671,Cavss,"Results showed that after the multiple-dose study, the mean clomipramine plus demethylclomipramine values of Cavss were 406.2 ng/mL-1 for the reference and 328.6 ng/mL-1 for the sustained-release dosage form.",Pharmacokinetics of a sustained-release dosage form of clomipramine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185671/),[ng] / [ml],328.6,273214,DB01242,Clomipramine
